Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Immunotherapy has become the major breakthrough and the most promising treatment, with the
host of development of tumor biology, molecular biology and immunology. It has become the
fourth tumor treatment model after traditional tumor therapies (surgery, chemotherapy,
radiotherapy) . Mesothelin, PSCA, CEA, HER2, MUC1 and EGFRvIII are potential targets and
spectacular paradigm in the diagnosis and treatment of pancreatic cancer. This study is for
evaluation of the safety and efficacy of Mesothelin, PSCA, CEA, HER2, MUC1, EGFRvIII targeted
and other CAR-T cell immunotherapy for pancreatic cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University